Clene Inc 8-K, filed Oct 20, 2026
Clene Inc. (CLNN)
About this 8-K
Clene Inc filed this 8-K on October 20, 2026, reporting on events of October 15, 2026.
Clene Inc. entered a fourth-year NIH Grant subaward amendment with New York University on October 15, 2026, for up to $7.2 million from September 1, 2026 to August 31, 2027, supporting CNM-Au8® expanded access for ALS. AI summary
Items reported
- Item 1.01: Entered into a material agreement
- Item 9.01: Financial statements and exhibits
|
|
|
|
|
(State or other jurisdiction
|
(Commission File Number)
|
(IRS Employer
|
|
of incorporation)
|
Identification No.)
|
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
The
|
| Exhibit Number | Exhibit Description | |
| 10.1 | Subaward Amendment, dated October 15, 2026, by and between Clene Nanomedicine, Inc. and NYU. | |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL). |
|
CLENE INC.
|
||
|
Date: October 20, 2026
|
By:
|
/s/ Robert Etherington
|
|
Robert Etherington
|
||
|
President and Chief Executive Officer
|
||
Exhibit 10.1
| Project No. 276219 | Subaward Amendment | ||||||||||||||
| Awarding Agency | National Institutes of Health (NIH) | Amendment No. | 1 | ||||||||||||
| PTE/Prime Award No. | 5U01NS136023-04 | Subaward No | 25-A0-00-1016064/OA6690 | ||||||||||||
| Pass-Through Entity (PTE) | Subrecipient | ||||||||||||||
| NYU Grossman School of Medicine | Entity Name | Clene Nanomedicine, Inc. | |||||||||||||
| grants.office@nyulangone.org | Contact Email | austin@clene.com | |||||||||||||
| Jinsy A. Andrews, MD | Principal Investigator | Benjamin Greenberg, M.D | |||||||||||||
| Project Title | Intermediate-sized Expanded Access Protocol for CNM-Au8 in Amyotrophic Lateral Sclerosis (ALS) | ||||||||||||||
| Cumulative Budget Period(s) | Amount Funded This Action | Total Amount of Funds Obligated to Date | |||||||||||||
| (Agreement Start Date) | (End Date of Latest Budget Period) | ||||||||||||||
| Start Date: | 09/01/2025 | End Date: | 08/31/2027 | $7,214,420.00 | $15,258,081.00 | ||||||||||
| Subrecipient Cost Share ☐ | Subject to FFATA ☒ | Subrecipient UEI | (Unique Entity Identifier - May leave blank if unchanged from prior Agreement) | SPPAJ9E6CK65 | |||||||||||
|
Amendment(s) to Original Terms and Conditions This Amendment revises the above-referenced Subaward Agreement as follows: |
|||||||||||||||
| ☒ Additional Budget Period | |||||||||||||||
| Additional budget period 09/01/2026 - 08/31/2027 is hereby added to this Subaward. | |||||||||||||||
| ☐ No Cost Extension | |||||||||||||||
| ☒ Additional Funding | |||||||||||||||
| Additional funding in the amount of $7,214,420.00 is hereby obligated to this Subaward. | |||||||||||||||
| ☐ Deobligation | |||||||||||||||
| Carryover is ________________ | |||||||||||||||
| ☐ Carryover Authorized | |||||||||||||||
| ☒ Detailed Budget/Scope of Work/Notice of Award Attached (Specify if the budget and Scope of Work are “New”, “Revised”, or “Supplemental” in dropdown or “Other”) | |||||||||||||||
| Budget, Budget Justification and NOA is incorporated by attachment to this Amendment. | |||||||||||||||
| ☒ Other (See Below) | |||||||||||||||
|
Carryover is not automatic and remains unchanged from the original Subaward.
Direct Costs: $6,273,409 Indirect Costs: $941,011 Total: $7,214,420
F&A rate applied on Modified Total Direct Costs: 15%
The following is added to Attachment 1; Administrative Capacity, Internal Controls, and Material Changes Disclosure Subrecipient certifies that it has disclosed, and shall timely disclose during the term of this Subaward, any material change that has affected or could reasonably be expected to affect its capacity to administer this Subaward, including administrative turnover, changes to accounting systems or business processes, or other organizational or compliance-related developments. Collaborator further certifies that it maintains internal controls in complianace with 2 C.F.R. § 200.303, financial management systems consistent with 2 C.F.R. § 200.302, and sufficient administrative capacity to perform and manage the Subaward in accordance with 2 C.F.R. Part 200 and the terms and conditions of the Prime Award. Collaborator acknowledges University’s monitoring obligations under 2 C.F.R. § 200.332 and agrees to provide prompt written notice, and supporting information upon request, concerning any material change relevant to Collaborator’s risk profile, compliance status, or performance under this Subaward.
|
|||||||||||||||
| For clarity: all amounts stated in this amendment are in United States Dollars. | |||||||||||||||
| All other terms and conditions of this Subaward Agreement remain in full force and effect. | |||||||||||||||
| By an Authorized Official of PTE: | By an Authorized Official of Subrecipient: | ||||||||||||||
| Date | Date | ||||||||||||||
| /s/ Samantha Ebel | 10/15/2026 | /s/ Rob Etherington | 10/12/26 | ||||||||||||
| Name | Samantha Ebel | Name | Rob Etherington | ||||||||||||
| Title | Senior Director- Research Contracts | Title | CEO, Clene Inc. | ||||||||||||